“… 23 , 24 , 43 In a randomized study involving 580 legs with GSV insufficiency, Rasmussen 43 and Lawaetz 24 found that the 5‐year occlusion rate was 25% lower in the UFGS group. These observations are consistent with several other reports on VU patients, where relapse rates in the treatment of VUs with UGFS ranged between 5% and 13% within a year, 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 whereas relapse rates of studies involving EVLA were ranging between 0% and 9%. 37 , 38 , 39 , 40 In a study by Wysong et al, 41 in which 30 patients were treated with EVLA in combination with foam sclerotherapy and/or phlebectomy of incompetent tributaries, no ulcer reoccurrence was observed within a median follow‐up time of 448 days.…”